SCYNEXIS

Q4 2021 Earnings Call

March 29, 2022

Forward Looking Statement

This presentation has been prepared by SCYNEXIS, Inc. (“we,” “us,” our,” SCYNEXIS,” or the “Company”) and is made for informational purposes only. The information includes forward-looking statements based on current expectations, including statements concerning our financial outlook for the future, leadership's expectations for our future financial and operational performance, as well as our business strategy. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Please refer to our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, including in each case under the caption "Risk Factors," and in other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements speak only as of today, March 29, 2022. SCYNEXIS undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. The information in this presentation is not intended for promotional purposes and not sufficient for prescribing decisions.

Agenda

Welcome & Opening Remarks	Debbie Etchison
Q4 Quarter & 2021 Overview	Marco Taglietti, M.D.
Commercial Highlights	Christine Coyne
Pipeline Update	David Angulo, M.D.
Financial Update	Larry R. Hoffman
Conclusion	Marco Taglietti, M.D.
Q&A	

SCYNEXIS

Marco Taglietti, M.D.

President and CEO

Q4 Quarter & 2021 Overview

Recent Accomplishments

R&D

- BREXAFEMME approval for VVC
- Positive Phase 3 results for rVVC
- Expanded Hospital Program

Commercial

- Launch of BREXAFEMME
- ~48% commercial lives coverage
- ~4,600 Rx/~ $1.1M in 2021 net sales

Corporate

- Out-Licensing of China Rights
- Closed 2021 with >$100M in Cash
- Cash Runway into Q2 2023

Making Ibrexafungerp a Successful Antifungal Franchise

Community Infections

Treatment of Vaginal Yeast Infections

BREXAFEMME®
(ibrexafungerp tablets)
Launched in Q3 2021
Anticipated rVVC approval by end of 2022

$400M+ in the U.S.

ibrexafungerp



First in class antifungal
Broad spectrum
Oral and IV

$700M-800M Antifungal Franchise

Hospital Infections

Ibrexafungerp for
Invasive Fungal Infections
Potential Approval in IC in 2024

$300M-400M in the U.S.

Goals for 2022

R&D

- Approval of recurrent VVC
- Advance Hospital Program

Commercial

- Grow BREXAFEMME adoption
- Expand insurance coverage

Corporate

- Build broad antifungal franchise
- Pursue international partnerships

SCYNEXIS

Christine Coyne

Chief Commercial Officer

Commercial Highlights

HCPs are Motivated by the Fungicidal Benefits of BREXAFEMME

BREXAFEMME is indicated for the treatment of vulvovaginal candidiasis (VVC)

- ✓ First and only oral fungicidal therapy that treats vaginal yeast infections
- ✓ Provides symptom relief with complete resolution

BREXAFEMME kills yeast, allowing for patients to be treated differently

- ✓ First oral, non-azole treatment for VVC
- ✓ Active against all *Candida* species that cause VVC, including azole-resistant strains

Doctors and patients appreciate the ease of one-day dosing

Source: ATU Market Research Conducted post launch in Q4 2021

BREXAFEMME's Robust Prescriber Base Grew in Q4 2021

Prescriber Growth Metrics

Q3 2021 (partial) vs. Q4 2021



- Approximately half of BREXAFEMME prescribers in Q3 2021 used the product again in Q4 2021
- More than 1,400 new prescribers used BREXAFEMME in Q4 2021

Source: IQVIA

Significant Q/Q Growth in BREXAFEMME TRx Volume

TRx Growth Metrics

Q3 2021 (partial) vs. Q4 2021



- Growing BREXAFEMME prescription (TRx) volume through effective field execution and marketing
- Q4 2021 TRx growth came from adding new prescribers and broader adoption among Q3 2021 prescribers

Source: IQVIA

Successful Commercial Strategy and Execution Continues to Generate Awareness Among Targeted HCPs

- **Strong BREXAFEMME awareness gains**
- **HCPs who have already prescribed BREXAFEMME indicate increasing use in the future**
- **BREXAFEMME's mechanism of action with proven activity against azole-resistant strains appeals to HCPs**
- **HCPs are excited about BREXAFEMME as the only FDA-approved, fungicidal treatment for vaginal yeast infections**

Output from the market research study is aligned with our commercial strategy and execution in the field

BREXAFEMME's early adoption among target HCPs indicates large future potential

Source: ATU Market Research conducted post launch in Q4 2021

BREXAFEMME Continues to Secure Favorable Formulary Coverage

Coverage Growth Metrics
Total Commercial Patient Lives
Q3 2021 (partial) vs. Q4 2021



- Over 81 million (48%) of commercially-insured lives covered for BREXAFEMME as of Q4 2021
- Large PBM's and payers have been responsive to the high unmet need and clinical value of the first non-azole therapy to treat vaginal yeast infections

Source: MMIT

SCYNEXIS

David Angulo, M.D.

Chief Medical Officer

R&D Pipeline Update

CANDLE Successfully Achieved Statistically Significant Superiority Over Placebo for Primary and Key Secondary Endpoints for RVVC

Primary Endpoint was Clinical Success

(absence of culture confirmed, presumed or suspected recurrence)

65.4% of patients receiving ibrexafungerp achieved clinical success by having no recurrence **at all**, compared to **53.1%** of placebo-treated patients (p=0.02)

Sustained Clinical Response

The advantage of ibrexafungerp over placebo was **sustained over the three-month follow-up period** and remained statistically significant (p=0.034)

Ibrexafungerp in Fluconazole Failures

24 patients who failed to respond to a **three-day** regimen of fluconazole received a one-day course of ibrexafungerp (300 mg BID).

71% successfully achieved a significant reduction or elimination of signs and symptoms after treatment with ibrexafungerp

- Ibrexafungerp was generally safe and well-tolerated.
- There were no serious drug-related adverse events, and no patients treated with ibrexafungerp discontinued therapy due to adverse events.
- The most commonly reported events were headaches and gastrointestinal events, which were mostly mild and generally consistent with the current BREXAFEMME label.

Ibrexafungerp Hospital & Community Clinical Programs

Exclusivity until 2035 with a stream of potential approvals in several indications



SCYNEXIS

Larry Hoffman

Interim Chief Financial Officer

Financial Update

2021 Q4 Financial Summary

Item	Q4 2021	Q4 2020	Highlights/Comments
Revenue	$ 0.6	$ 0.0	Net product revenue
R&D Expenses	$ 7.7	$ 10.2	Completion of trials related to the approval of BREXAFEMME
SG&A Expenses	$ 15.0	$5.2	Commercial launch in August 2021
Net Loss	$ (29.2)	$ (42.7)	Recorded non-cash income related to warrant expirations and stock price

$ Millions

2021 Annual Financial Summary

Item	2021	2020	Highlights/Comments
Revenue	$ 13.2	$ 0.0	$1.1 million net product revenue $12.1 million license agreement revenue
R&D Expenses	$ 23.8	$ 36.5	Completion of trials related to the approval of BREXAFEMME
SG&A Expenses	$ 49.9	$ 14.6	Commercial launch in August 2021
Net Loss	$ (32.9)	$ (55.2)	Recorded non-cash income related to warrant expirations and stock price
Ending Cash Balance	$ 104.5	$ 93.0	Warrant exercises supplemented cash on hand

$ Millions

Cash Balance is Strong

Cash runway into the second quarter of 2023

Cash and cash equivalents of $104.5 million as of December 31, 2021, with an additional $9.7 million raised in the first quarter of 2022 from sale of NJ NOLs and third tranche of Hercules/SVB debt facility

Eligible to receive up to $112 million in future long-term development and commercial milestones, plus low double-digit royalties on net product sales from partner Hansoh Pharma in Greater China

Potential for additional ex-U.S. business development opportunities

Summary

1. BREXAFEMME launch is making great strides with HCPs and patients, and we anticipate expanding the labeling by the end of this year

2. R&D pipeline is extremely robust, and we expect to enroll the first patient in our MARIO trial in Q2 with a stream of approvals in the years to come

3. Strong financial position with a cash runway into the second quarter of 2023

Q&A